Chinese developers of immune checkpoint inhibitors including PD-1/L1 antibodies are making fresh progress in clinical trials that could pave the way for eventual US regulatory nods in the space of relatively rare small cell lung cancer.
The latest developments seem to add new momentum into Chinese-made checkpoint inhibitors in the wake of prior setbacks, including those encountered by Innovent Biologics, Inc.’s Tyvyt (sintilimab) and